Technical advances in NK cell-based cellular immunotherapy

doi:10.20892/j.issn.2095-3941.2019.0187

. 2019 Nov;16(4):647-654.

doi: 10.20892/j.issn.2095-3941.2019.0187.

Technical advances in NK cell-based cellular immunotherapy

Fang Fang^{1

2

3

4}, Wei Wang^{2

3

4}, Minhua Chen^{2

3

4}, Zhigang Tian^{1

2

3

4}, Weihua Xiao^{1

2

3

4}

Affiliations

¹ Department of Oncology of The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
² Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China.
³ Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.
⁴ Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China.

PMID: 31908885
PMCID: PMC6936239
DOI: 10.20892/j.issn.2095-3941.2019.0187

Technical advances in NK cell-based cellular immunotherapy

Fang Fang et al. Cancer Biol Med. 2019 Nov.

. 2019 Nov;16(4):647-654.

doi: 10.20892/j.issn.2095-3941.2019.0187.

Authors

Fang Fang^{1

2

3

4}, Wei Wang^{2

3

4}, Minhua Chen^{2

3

4}, Zhigang Tian^{1

2

3

4}, Weihua Xiao^{1

2

3

4}

Affiliations

¹ Department of Oncology of The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
² Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China.
³ Institute of Immunology, University of Science and Technology of China, Hefei 230027, China.
⁴ Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China.

PMID: 31908885
PMCID: PMC6936239
DOI: 10.20892/j.issn.2095-3941.2019.0187

Abstract

Natural killer (NK) cells represent a promising future for tumor immunotherapy because of their unique biological functions and characteristics. This review focuses on technical advances in NK cell-based cellular immunotherapy and summarizes the developments of recent years in cell sources, genetic modification, manufacturing systems, clinical programs, and outcomes. Future prospects and challenges in NK cell immunotherapy are also discussed, including off-the-shelf NK cell exploitation, automatic and closed manufacturing systems, cryopreservation, and therapies involving regulatory checkpoints.

Keywords: Natural killer cell; adoptive cell transfer; genetic modification; immunotherapy.

PubMed Disclaimer

Cited by

Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Elahi R, et al. Stem Cell Rev Rep. 2021 Dec;17(6):2081-2106. doi: 10.1007/s12015-021-10246-3. Epub 2021 Sep 2. Stem Cell Rev Rep. 2021. PMID: 34472037 Free PMC article. Review.
An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood.
Nakazawa T, Maeoka R, Morimoto T, Matsuda R, Nakamura M, Nishimura F, Yamada S, Nakagawa I, Park YS, Ito T, Nakase H, Tsujimura T. Nakazawa T, et al. Regen Ther. 2023 Jun 1;24:32-42. doi: 10.1016/j.reth.2023.05.006. eCollection 2023 Dec. Regen Ther. 2023. PMID: 37303464 Free PMC article.
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity.
Wang Y, Wang M, Yu K, Xu S, Qiu P, Lyu Z, Cui M, Zhang Q, Xu Y. Wang Y, et al. Cancer Biol Med. 2023 Mar 24;20(3):218-28. doi: 10.20892/j.issn.2095-3941.2022.0513. Cancer Biol Med. 2023. PMID: 36971132 Free PMC article.
Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
Jung D, Baek YS, Lee IJ, Kim KY, Jang H, Hwang S, Jung J, Moon YW, Park KS, Choi YS, An HJ. Jung D, et al. J Exp Clin Cancer Res. 2021 Oct 23;40(1):333. doi: 10.1186/s13046-021-02089-0. J Exp Clin Cancer Res. 2021. PMID: 34686187 Free PMC article.
Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.
Bakhtiyaridovvombaygi M, Yazdanparast S, Kheyrandish S, Safdari SM, Amiri Samani F, Sohani M, Jaafarian AS, Damirchiloo F, Izadpanah A, Parkhideh S, Mikanik F, Roshandel E, Hajifathali A, Gharehbaghian A. Bakhtiyaridovvombaygi M, et al. Biomark Res. 2024 Jul 17;12(1):66. doi: 10.1186/s40364-024-00610-z. Biomark Res. 2024. PMID: 39020411 Free PMC article. Review.

See all "Cited by" articles

References

1. Ramos CA, Heslop HE, Brenner MK CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67:165–83. doi: 10.1146/annurev-med-051914-021702. - DOI - PMC - PubMed
1. Handgretinger R, Lang P, André MC Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016;127:3341–9. doi: 10.1182/blood-2015-12-629055. - DOI - PubMed
1. He YK, Tian ZG NK cell education via nonclassical MHC and non-MHC ligands. Cell Mol Immunol. 2017;14:321–30. doi: 10.1038/cmi.2016.26. - DOI - PMC - PubMed
1. Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, et al The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012;73:248–57. doi: 10.1016/j.humimm.2011.12.015. - DOI - PubMed
1. Dalle JH, Menezes J, Wagner E, Blagdon M, Champagne J, Champagne MA, et al Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res. 2005;57:649–55. doi: 10.1203/01.PDR.0000156501.55431.20. - DOI - PubMed

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Other Literature Sources
- The Lens - Patent Citations Database

[1] Ramos CA, Heslop HE, Brenner MK CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67:165–83. doi: 10.1146/annurev-med-051914-021702. - DOI - PMC - PubMed

[2] Ramos CA, Heslop HE, Brenner MK CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67:165–83. doi: 10.1146/annurev-med-051914-021702. - DOI - PMC - PubMed

[3] Handgretinger R, Lang P, André MC Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016;127:3341–9. doi: 10.1182/blood-2015-12-629055. - DOI - PubMed

[4] Handgretinger R, Lang P, André MC Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016;127:3341–9. doi: 10.1182/blood-2015-12-629055. - DOI - PubMed

[5] He YK, Tian ZG NK cell education via nonclassical MHC and non-MHC ligands. Cell Mol Immunol. 2017;14:321–30. doi: 10.1038/cmi.2016.26. - DOI - PMC - PubMed

[6] He YK, Tian ZG NK cell education via nonclassical MHC and non-MHC ligands. Cell Mol Immunol. 2017;14:321–30. doi: 10.1038/cmi.2016.26. - DOI - PMC - PubMed

[7] Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, et al The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012;73:248–57. doi: 10.1016/j.humimm.2011.12.015. - DOI - PubMed

[8] Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, et al The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012;73:248–57. doi: 10.1016/j.humimm.2011.12.015. - DOI - PubMed

[9] Dalle JH, Menezes J, Wagner E, Blagdon M, Champagne J, Champagne MA, et al Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res. 2005;57:649–55. doi: 10.1203/01.PDR.0000156501.55431.20. - DOI - PubMed

[10] Dalle JH, Menezes J, Wagner E, Blagdon M, Champagne J, Champagne MA, et al Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res. 2005;57:649–55. doi: 10.1203/01.PDR.0000156501.55431.20. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Technical advances in NK cell-based cellular immunotherapy

Affiliations

Technical advances in NK cell-based cellular immunotherapy

Authors

Affiliations

Abstract

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources